Raymond W. Cohen
Mr. Cohen serves as Chairman of the Board of LoneStar Heart, Inc. With over 30 years of experience in leading medical device companies, Mr. Cohen is an accredited public company director. From 2010 to 2012, he served as CEO of privately-held venture capital backed Vessix Vascular which was acquired by Boston Scientific in November 2012. He spent nearly a decade as Chairman & CEO of Nasdaq-listed Cardiac Science Inc. ranked as the 4th fastest growing company in U.S. in 2004. Currently, Mr. Cohen is President and CEO of Irvine-based Axonics Modulation Technologies, a developer of sacral neuromodulation devices. He also serves as Chairman of the board of directors at a number of private and publicly traded life science companies including Lombard Medical (Nasdaq: EVAR – endovascular AAA stent graft), BioLife Solutions (Nasdaq: BLFS – preservation media for human cells), and Syncroness, Inc. (contract engineering). He also serves as a director of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI – Oncology drugs) and JenaValve Technologies, Inc. (transcatheter aortic valve replacement systems).
Mr. Ahmann serves as CEO of LoneStar Heart, Inc. With 30 years of experience in the biotech and medical device industries, Mr. Ahmann has held executive management positions ranging from operations management to new product development and sales and marketing. He was instrumental in the foundation and development of start-ups such as Chimeric Therapies, Inc., Nephrogenex, Inc., Allvivo, Inc., and CardioPolymers, Inc. The latter was acquired in 2010 by LoneStar Heart to develop the Company’s lead implantable hydrogel technology. He has also been a strategy consultant to start-ups and venture capital firms in the cardiovascular, oncology, and stem cell therapy sectors. Previously, Mr. Ahmann held management positions in Europe and North America at Baxter International’s Biotech Group and Cardiovascular Group (now Edwards LifeSciences). Among many technologies, he launched the first comprehensive system for the collection, processing, storage, and administration of hematopoietic stem cells. A German citizen who grew up in Mexico, Mr. Ahmann is a native Spanish, German, and English speaker with strong ties to the European medical market. Mr. Ahmann holds a BBA with Honors from the University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.
Andrew J. S. Coats, M.D.
A highly respected academic researcher in heart failure, Prof. Andrew Coats trained in medicine at the Universities of Oxford and Cambridge, and holds higher doctorates from Oxford and Imperial College and an M.B.A. from the London Business School. He was the first Viscount Royston Professor at the National Heart and Lung Institute, becoming director of cardiology at the Royal Brompton Hospital, and then associate medical director of the Royal Brompton and Harefield NHS Trust. He was then dean of medicine at the University of Sydney, becoming deputy vice chancellor in 2006. Currently, Prof. Coats is joint Academic Vice-President and Director of the Monash-Warwick Universities Alliance strategy. He is editor-in-chief of the International Journal of Cardiology and has more than 1,000 publications, including 450 full papers in peer-reviewed journals and more than 18,000 career citations. Dr. Coats has served as the chairman or steering committee member for many major morbidity/mortality trials. He has received the Linacre Medal of the Royal College of Physicians and gave the Inaugural Michael L. Pollock Memorial Lecture of the American Heart Association. In 2010, Dr. Coats was appointed the Norwich Research Park Professor-at-large, University of East Anglia. He is a scientific founder and founding board member of Myotec Therapeutics Ltd. that later merged to become PsiOxus, Ltd.
Charles Chon, CFA is Partner and Managing Director at Ally Bridge Group (ABG), a global healthcare fund based in Hong Kong. Mr. Chon leads ABG’s Medical Technologies effort and has been instrumental in numerous ABG investments. Currently, he serves as a director on the boards of Minneapolis-based companies, NxThera and Conventus Orthopedics. Prior to joining ABG as a founding member in 2013, Mr. Chon was a healthcare public equities research analyst for over 13 years on both the buy-side and sell-side. The majority of that time was at Goldman Sachs as Vice President, senior equity research analyst on the US medical devices team. From there, Mr. Chon became Sector Head, US medical devices research at Stifel Nicolaus. Mr. Chon holds the CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.
Stephan Rietiker, MD
Dr. Stephan Rietiker, a citizen of Switzerland, received his medical doctorate from the University of Zurich in 1982 and is also qualified to practice medicine in the United States. He spent five years practicing internal medicine before moving into the Healthcare industry. He began his career with Roche in 1987 and thereafter held several senior positions in marketing / general management with Boehringer Mannheim and then Schering Plough. Subsequently, he became Vice President and General Manager, Europe for Covance Central Laboratory Services. In 2001, he was appointed President and CEO of Sulzer Medica (later Centerpulse) and was instrumental in resolving a landmark legal settlement in a major U.S. litigation. He was also responsible for restructuring the company which ultimately led to its acquisition by Zimmer in 2003. After a year as CEO and Director at Pendragon Medical AG, he took on the role of Executive Director and CEO at IMI Intelligent Medical Implants in 2004. In 2006, Dr. Rietiker left IMI and incorporated AurigaVision AG, a Switzerland based investment platform that focuses on promising developmental-stage healthcare companies, including LifeWatch, AG. In June 2014, following a four month period as an Executive Board Member and Interim CEO of LifeWatch AG, the Board appointed Dr. Rietiker as the Company’s CEO. Dr. Rietiker has also been a Senior Advisor to Brown Brothers Harriman’s Corporate Finance team from 2006 – 2014.
Mr. Yu is Founder and CEO of Ally Bridge Group, a global healthcare-focused investment group based in Hong Kong and the US, and of Themes Investment Partners, a China-focused private equity fund. In 2015, Mr. Yu's Ally Bridge Group executed a joint offer to take Wuxi private for USD3.3 billion, the largest healthcare private equity deal in Asia ex-Japan. Mr. Yu is a Wuxi director. His expertise in forming strategic transactions between emerging players and industry leaders is exemplified by his successful investment in Chinese medical devices company Lifetech (HKSE: 1302) and his role that company’s landmark partnership deal with Medtronic. His funds’ portfolios include innovative biopharmaceutical and medtech companies in China, the US and Europe, covering a number of major therapeutic areas ranging from oncology to cardiology, diabetes, ophthalmology, neurology, and others. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong and also worked at Moody's in New York, and then Credit Suisse in London and Hong Kong.